Japan Academia Progresses Novel Melanoma Drug Despite Pharma 'Reluctance'

Promising Phase II Results

Academia-developed novel oral PAI-1 inhibitor in combination with Opdivo showed a strong response rate in PD-1 treated melanoma patients with certain disease characteristics and could represent a new breakthrough for a class with no clinical stage competitors. 

National funding and an original research collaboration platform by dermatologists made the Japanese P2 successful.
National funding and an original research collaboration platform by dermatologists made the Japanese P2 successful. • Source: Shutterstock

A novel molecule originated by Japanese academia has recorded an unusual success in a Phase II trial for a challenging dermatologic oncology indication, and appears to be the only drug globally in its class to be in active clinical development.

Tohoku University recently announced positive top-line results from the investigator-led, 34-patient study for its in-house-developed oral plasminogen activator inhibitor-1 (PAI-1)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia